恶性间皮瘤的靶向与免疫治疗  

Targeted therapy and immunotherapy for malignant mesothelioma

作　　者：杨俊豪 赵林[1] YANG Junhao;ZHAO Lin(Department of Oncology,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100730,China)

机构地区：[1]中国医学科学院、北京协和医学院、北京协和医院、肿瘤内科,北京100730

出　　处：《基础医学与临床》2024年第10期1342-1349,共8页Basic and Clinical Medicine

基　　金：中央高水平医院临床科研专项专科提升项目(2022-PUMCH-B-051)。

摘　　要：恶性间皮瘤(malignant mesothelioma,MMe)是一种来源于间皮组织的恶性肿瘤,多发生在胸膜、心包膜和腹膜等处,由于难以治愈的特点,对其治疗的研究一直备受关注。传统的治疗手段包括手术、化疗和放疗,但因疗效有限,患者生存率仍然较低。因此,寻找新的治疗方法对于改善间皮瘤患者的预后至关重要。靶向治疗和免疫治疗作为新兴的癌症治疗手段,通过针对肿瘤细胞或免疫细胞的特定靶点来抑制肿瘤的生长和转移,为间皮瘤的治疗带来了新的希望。本文围绕间皮瘤的靶向治疗与免疫治疗新进展进行综述。Malignant mesothelioma(MMe)is a malignant tumor originating from mesothelial tissues,occurring mostly in locations like pleura,pericardium and peritoneum.The extensive research on its treatment has been carried on as tackling to the challenge of poor prognosis of the disease.Conventional treatment modalities including surgery,chemotherapy and radiotherapy all exhibit limited efficacy,resulting in persistently low survival rates.Hence,exploring novel therapeutic approaches is paramount for improving the prognosis of mesothelioma patients.Targeted therapy and immunotherapy,as emerging cancer treatment modalities,exert their effects by targeting specific molecular markers on tumor cells or immune cells,thus inhibiting tumor growth and metastasis,thereby offering new hope for mesothelioma treatment.This article provides a comprehensive review of recent research progress in targeted therapy and immunotherapy for mesothelioma.

关 键 词：间皮瘤 靶向治疗 免疫治疗 溶瘤病毒 CAR-T 

分 类 号：R730.51[医药卫生—肿瘤] R730.53[医药卫生—临床医学] R730.54